Author response for "Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: <scp>SOUL</scp> , a randomized trial, design and baseline characteristics"